<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">HJBM</journal-id><journal-title-group><journal-title>Hans Journal of Biomedicine</journal-title></journal-title-group><issn pub-type="epub">2161-8976</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/HJBM.2020.104012</article-id><article-id pub-id-type="publisher-id">HJBM-37775</article-id><article-categories><subj-group subj-group-type="heading"><subject>HJBM20200400000_75214986.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  用于治疗系统性红斑狼疮的脐带间充质干细胞的产品质量控制的研究
  Quality Control of Umbilical Cord Mesenchymal Stem Cells for the Treatment of Systemic Lupus Erythematosus
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>珂慧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郭</surname><given-names>伟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>济南赛尔生物科技股份有限公司，山东 济南</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>24</day><month>07</month><year>2020</year></pub-date><volume>10</volume><issue>04</issue><fpage>82</fpage><lpage>94</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：分离培养符合用于治疗系统性红斑狼疮的产业化的脐带间充质干细胞(UC-MSC)，并进行脐带间充质干细胞产品质量控制的研究。方法：从脐带中通过贴壁法获得间充质干细胞，传代培养后，采用无血清培养体系扩增培养UC-MSC。通过流式细胞术和诱导分化技术，检测其中干细胞含量、细胞总数、细胞活率，并取样进行细菌检测、内毒素检测、支原体检测，满足质量标准方能应用。选取BALB/c小鼠，进行pristane造模，将BALB/c小鼠随机分为对照组、模型组和治疗组，对照组和模型组给予等量的生理盐水；治疗组给予UC-MSC (4 &#215; 105 cells/ml)，0.2 ml。进行抗双链DNA (ds-DNA)抗体、系统性红斑狼疮活动度评分(SLEDAI)和常规血液检查。通过裸鼠致瘤性实验、毒性试验等评估脐带间充质干细胞产品的安全性。结果：经过技术改造升级，无血清培养的UC-MSC贴壁生长，主要为典型的成纤维样细胞形态，可传15代以上，第5代MSCs高表达CD73、CD105、CD90、CD44；低表达CD34、CD45和HLA-DR；在不同的诱导条件下，脐带MSCs可被诱导分化为成骨细胞和软骨细胞。治疗组UC-MSC给药30天，抗ds-DNA抗体水平明显降低，与对照组相比差异有显著性意义，疾病活动度评分明显降低，蛋白尿、血肌酐、尿素氮等指标得到改善，与模型组比较差异均具有统计学意义(P &lt; 0.05)。结论：本研究建立了工业化生产UC-MSC的质量管理体系，验证了UC-MSC治疗系统性红斑狼疮的安全性及有效性，为后续开展UC-MSC治疗系统性红斑狼疮的临床试验开展提供理论依据和技术支持。
   Objective: To isolate and cultivate umbilical cord mesenchymal stem cells (UC-MSC) suitable for the treatment of systemic lupus erythematosus (SLE). Methods: MSCs were obtained from umbilical cord by adherent method. After subculture, UC-MSC was amplified by serum-free culture system. Through flow cytometry and induced differentiation technology, stem cell content, total number of cells and cell viability were detected, and samples were taken for bacterial detection, endotoxin detection and mycoplasma detection to meet the quality standards before application. To establish sound technical procedures and quality standards for the production, packaging, storage and transportation of umbilical cord mesenchymal stem cells; complete the quality control system plan, BALB/C mice were selected and pristane was used for modeling. BALB/C mice were randomly di-vided into control group, model group and treatment group. The treatment group was given UC-MSC (4 &#215; 105 cells/ml), 0.2 ml. Antidouble-stranded DNA (ds-DNA) antibodies, systemic lupus erythem-atous Activity score (SLEDAI), and routine blood tests were performed. The safety of umbilical cord mesenchymal stem cells was evaluated by tumorigenicity test and toxicity test in nude mice. Re-sults and Conclusion: After technical modification and upgrading, the serum-free culture of UC-MSCs grew adherently, mainly in the form of typical fibroblasts, which could be transmitted over 15 gen-erations. The fifth generation MSCs showed high expression of CD73, CD105, CD90, CD44 and low expression of CD34, CD45 and HLA-DR. Under different induction conditions, umbilical cord MSCs could be induced to differentiate into osteoblasts and chondrocytes. After 30 days of UC-MSC ad-ministration, the level of anti-DS -DNA antibody in the treatment group was significantly reduced, with significant differences compared with the control group. The disease activity score was signifi-cantly reduced, and indicators such as proteinuria, serum creatinine and urea nitrogen were im-proved, with statistically significant differences compared with the model group (P &lt; 0.05). This study established a quality management system for the industrial production of UC-MSC, verified the safety and effectiveness of UC-MSC in the treatment of systemic lupus erythematosus, and pro-vided theoretical basis and technical support for subsequent clinical trials of UC-MSC in the treat-ment of systemic lupus erythematosus.
 
</p></abstract><kwd-group><kwd>UC-MSC，质量控制，系统性红斑狼疮，免疫调节, UC-MSC</kwd><kwd> Quality Control</kwd><kwd> Systemic Lupus Erythematosus</kwd><kwd> The Immune Regulation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：分离培养符合用于治疗系统性红斑狼疮的产业化的脐带间充质干细胞(UC-MSC)，并进行脐带间充质干细胞产品质量控制的研究。方法：从脐带中通过贴壁法获得间充质干细胞，传代培养后，采用无血清培养体系扩增培养UC-MSC。通过流式细胞术和诱导分化技术，检测其中干细胞含量、细胞总数、细胞活率，并取样进行细菌检测、内毒素检测、支原体检测，满足质量标准方能应用。选取BALB/c小鼠，进行pristane造模，将BALB/c小鼠随机分为对照组、模型组和治疗组，对照组和模型组给予等量的生理盐水；治疗组给予UC-MSC (4 &#215; 10<sup>5</sup> cells/ml)，0.2 ml。进行抗双链DNA (ds-DNA)抗体、系统性红斑狼疮活动度评分(SLEDAI)和常规血液检查。通过裸鼠致瘤性实验、毒性试验等评估脐带间充质干细胞产品的安全性。结果：经过技术改造升级，无血清培养的UC-MSC贴壁生长，主要为典型的成纤维样细胞形态，可传15代以上，第5代MSCs高表达CD73、CD105、CD90、CD44；低表达CD34、CD45和HLA-DR；在不同的诱导条件下，脐带MSCs可被诱导分化为成骨细胞和软骨细胞。治疗组UC-MSC给药30天，抗ds-DNA抗体水平明显降低，与对照组相比差异有显著性意义，疾病活动度评分明显降低，蛋白尿、血肌酐、尿素氮等指标得到改善，与模型组比较差异均具有统计学意义(P &lt; 0.05)。结论：本研究建立了工业化生产UC-MSC的质量管理体系，验证了UC-MSC治疗系统性红斑狼疮的安全性及有效性，为后续开展UC-MSC治疗系统性红斑狼疮的临床试验开展提供理论依据和技术支持。</p></sec><sec id="s2"><title>关键词</title><p>UC-MSC，质量控制，系统性红斑狼疮，免疫调节</p></sec><sec id="s3"><title>Quality Control of Umbilical Cord Mesenchymal Stem Cells for the Treatment of Systemic Lupus Erythematosus</title><p>Kehui Song, Wei Guo</p><p>Jinan Cell Biotechnology Co. LTD., Jinan Shandong</p><p><img src="//html.hanspub.org/file/3-1530151x4_hanspub.png" /></p><p>Received: Aug. 31<sup>st</sup>, 2020; accepted: Sep. 15<sup>th</sup>, 2020; published: Sep. 22<sup>nd</sup>, 2020</p><p><img src="//html.hanspub.org/file/3-1530151x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To isolate and cultivate umbilical cord mesenchymal stem cells (UC-MSC) suitable for the treatment of systemic lupus erythematosus (SLE). Methods: MSCs were obtained from umbilical cord by adherent method. After subculture, UC-MSC was amplified by serum-free culture system. Through flow cytometry and induced differentiation technology, stem cell content, total number of cells and cell viability were detected, and samples were taken for bacterial detection, endotoxin detection and mycoplasma detection to meet the quality standards before application. To establish sound technical procedures and quality standards for the production, packaging, storage and transportation of umbilical cord mesenchymal stem cells; complete the quality control system plan, BALB/C mice were selected and pristane was used for modeling. BALB/C mice were randomly divided into control group, model group and treatment group. The treatment group was given UC-MSC (4 &#215; 10<sup>5</sup> cells/ml), 0.2 ml. Antidouble-stranded DNA (ds-DNA) antibodies, systemic lupus erythematous Activity score (SLEDAI), and routine blood tests were performed. The safety of umbilical cord mesenchymal stem cells was evaluated by tumorigenicity test and toxicity test in nude mice. Results and Conclusion: After technical modification and upgrading, the serum-free culture of UC-MSCs grew adherently, mainly in the form of typical fibroblasts, which could be transmitted over 15 generations. The fifth generation MSCs showed high expression of CD73, CD105, CD90, CD44 and low expression of CD34, CD45 and HLA-DR. Under different induction conditions, umbilical cord MSCs could be induced to differentiate into osteoblasts and chondrocytes. After 30 days of UC-MSC administration, the level of anti-DS -DNA antibody in the treatment group was significantly reduced, with significant differences compared with the control group. The disease activity score was significantly reduced, and indicators such as proteinuria, serum creatinine and urea nitrogen were improved, with statistically significant differences compared with the model group (P &lt; 0.05). This study established a quality management system for the industrial production of UC-MSC, verified the safety and effectiveness of UC-MSC in the treatment of systemic lupus erythematosus, and provided theoretical basis and technical support for subsequent clinical trials of UC-MSC in the treatment of systemic lupus erythematosus.</p><p>Keywords:UC-MSC, Quality Control, Systemic Lupus Erythematosus, The Immune Regulation</p><disp-formula id="hanspub.37775-formula13"><graphic xlink:href="//html.hanspub.org/file/3-1530151x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/3-1530151x7_hanspub.png" /> <img src="//html.hanspub.org/file/3-1530151x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>系统性红斑狼疮(systemic lupus erythematosus，SLE)是一种常见的自身免疫性疾病。主要特征为Ｔ、Ｂ淋巴细胞活化异常产生大量自身抗体并与体内相应的自身抗原结合形成相应的免疫复合物，对肾、心血管、神经、肌肉骨骼和皮肤等多器官产生损害 [<xref ref-type="bibr" rid="hanspub.37775-ref1">1</xref>]。84%~90%的患者会累及肾脏出现肾功能损伤，即狼疮性肾炎(lupusnephritis, LN)，主要临床表现为蛋白尿、血尿等 [<xref ref-type="bibr" rid="hanspub.37775-ref2">2</xref>]。SLE全球发病率为12.5~39/10万，我国的患病率为0.7~1/1000，女性：男性６~10：1，20~40岁是高发年龄 [<xref ref-type="bibr" rid="hanspub.37775-ref3">3</xref>]。目前SLE无理想的治疗方案，临床上主要是应用糖皮质激素和免疫抑制剂，但仍有部分患者出现复发或反复活动，长期使用激素和免疫抑制同样增加了患者的潜在致死率 [<xref ref-type="bibr" rid="hanspub.37775-ref4">4</xref>]。该病早期死亡风险较高，特别是年轻人，高达45%的患者出现早期器官损害，这与疾病持续活动或肾脏疾病有关，其中肾脏受累的患者，40%~50%的患者死亡率高于预期的8倍，且临床治疗不佳 [<xref ref-type="bibr" rid="hanspub.37775-ref5">5</xref>]。与皮质类固醇激素相比，环磷酰胺治疗并没有改善患者的生存率 [<xref ref-type="bibr" rid="hanspub.37775-ref6">6</xref>]，有实验比较过霉酚酸酯和静脉环磷酰胺治疗狼疮性肾炎的疗效，患者完全缓解率分别仅有8.6%和8.1%，需要寻找更安全、更有效的方法 [<xref ref-type="bibr" rid="hanspub.37775-ref7">7</xref>]。</p><p>干细胞(stem cell)是一类具有自我更新和多向分化潜能的细胞群体，具有可塑性。在一定的条件下能分化为组织细胞，如成骨细胞、成软骨细胞、脂肪细胞、神经细胞、内皮细胞及心肌细胞。根据干细胞的分化潜能大小分为三类：全能干细胞，多能干细胞和单能干细胞。按其来源可以分为胚胎干细胞和成体干细胞。胚胎干细胞(Embryonic Stem Cell, ESC)是从早期胚胎或原始性腺种分离出来的一类干细胞，具备体内外发育分化的全能性。其它从成体组织如骨髓、肌肉等获得的干细胞，我们称之为成体干细胞(Adult Stem Cell, ASC)，只具有部分发育分化功能，只能分化为一种或多种功能细胞。人体几乎所有组织都存在ASC。</p><p>间充质干细胞(Mesenchymal stem cells, MSCs)是一类具有高度自我更新和多向分化潜能的成体干细胞。最早在骨髓中发现，后经研究证实，真皮、脂肪组织、肌肉、外周血、脐带血、脐带静脉内皮下层、胎盘中也发现MSCs。MSCs起源于中胚层，具有向内、中、外三胚层的多种细胞分化的能力。MSCs除了具有支持造血的功能，还具有免疫抑制作用，其独特的生物学特性及其临床应用越来越受到人们的重视，现在已成为多种疾病细胞治疗的首选。</p></sec><sec id="s6"><title>2. 材料与方法</title><sec id="s6_1"><title>2.1. 实验材料</title><sec id="s6_1_1"><title>2.1.1. 实验动物</title><p>BALB/c小鼠45只，清洁级，6周龄，雄性，购自山东大学实验动物中心。</p></sec><sec id="s6_1_2"><title>2.1.2. 实验试剂</title><p>淋巴细胞分离液(天津市灏洋生物制品科技责任有限公司)</p><p>胰酶-EDTA(Gibco公司)</p><p>胎牛血清(Gibco公司)</p><p>MEM-α培养基(Hyclone公司)</p><p>DMEM培养基(Hyclone公司)</p><p>UltraGRO<sup>TM</sup>细胞营养添加物(美国Helios公司)</p><p>青霉素&amp;链霉素(Hyclone公司)</p><p>乙醇(国产分析纯)</p><p>PBS (Gibco)</p><p>台盼蓝(Sigma公司)</p><p>DMSO (Sigma公司)</p><p>Pristane (Sigma 公司)</p><p>FITC-CD90抗体(BD公司)</p><p>PE-CD73抗体(BD公司)</p><p>PE-CD105抗体(BD公司)</p><p>PE-CD44抗体(BD公司)</p><p>FITC-CD34抗体(BD公司)</p><p>PE-CD45抗体(BD公司)</p><p>FITC-HLA-DR抗体(BD公司)</p><p>细胞因子添加物FGF、PDGF、VEGF、EGF (美国R &amp; D公司)</p><p>细胞培养板、细胞培养瓶(美国Corning公司)</p></sec><sec id="s6_1_3"><title>2.1.3. 实验仪器</title><p>流式细胞仪：Millipore公司</p><p>倒置显微镜：CKX31，OLYMPUS公司</p><p>CO<sub>2</sub>培养箱：HF240，上海力申科学仪器有限公司</p><p>酶标仪：BIO-TEK，ELx 808</p></sec></sec><sec id="s6_2"><title>2.2. 实验方法</title><sec id="s6_2_1"><title>2.2.1. 无血清培养脐带间充质干细胞</title><p>1) 细胞原代培养及无血清传代培养</p><p>UC-MSC细胞原代培养：采用组织块贴壁法。健康足月胎儿脐带经产妇同意后，根据伦理委员会通过的指导原则采集。75%酒精浸泡消毒，将脐带剪成2~3 cm小段，用生理盐水加双抗冲洗5~6次，洗去脐带表面血液。剥离脐静脉及脐动脉，将脐带剪成1 mm<sup>3</sup>，平铺于T150的细胞培养瓶中，37℃ 5% CO<sub>2</sub>培养箱放置24 h，加含有胎牛血清的MEM-α培养基。用倒置显微镜观察细胞的生长情况，4~6天后换液，弃去非贴壁细胞后，每3天换液一次。</p><p>UC-MSC的无血清传代与培养：当细胞长至80%融合时，用生理盐水冲洗两遍，0.25%胰蛋白酶37℃消化1 min，按照5 &#205; 10<sup>4</sup>细胞/ml密度，使用含有UltraGRO<sup>TM</sup>细胞营养添加物的DMEM培养基与含有胎牛血清的DMEM培养基1:3配比的混合培养基进行传代，记为P2。当细胞长至80%融合时，用生理盐水冲洗两遍，0.25%胰蛋白酶37℃消化1min，按照5 &#205; 10<sup>4</sup>细胞/ml密度，使用含有UltraGRO<sup>TM</sup>细胞营养添加物的DMEM培养基与含有胎牛血清的DMEM培养基1:2配比的混合培养基进行传代，记为P3。当细胞长至80%融合时，用生理盐水冲洗两遍，0.25%胰蛋白酶37℃消化1 min，按照5 &#205; 10<sup>4</sup>细胞/ml密度，使用含有UltraGRO<sup>TM</sup>细胞营养添加物的DMEM培养基与含有胎牛血清的DMEM培养基1:1配比的混合培养基进行传代，记为P3。当细胞长至80%融合时，用生理盐水冲洗两遍，0.25%胰蛋白酶37℃消化1min，按照5 &#205; 10<sup>4</sup>细胞/ml密度，使用含有UltraGRO<sup>TM</sup>细胞营养添加物的DMEM培养基与含有胎牛血清的DMEM培养基2:1配比的混合培养基进行传代，记为P4。当细胞长至80%融合时，用生理盐水冲洗两遍，0.25%胰蛋白酶37℃消化1min，按照5 &#205; 10<sup>4</sup>细胞/ml密度，使用含有UltraGRO<sup>TM</sup>细胞营养添加物的DMEM培养基进行传代，记为P4。P4之后传代均用含有UltraGRO<sup>TM</sup>细胞营养添加物的DMEM培养基进行传代。</p><p>2) 常规观察和检测</p><p>a) 倒置显微镜观察</p><p>取第P5的UC-MSC进行常规倒置显微镜观察和HE染色。</p><p>b) 扫描电子显微镜观察</p><p>取第5代UC-MSC进行扫描电子显微镜观察。预置的盖玻片在爬满细胞后取出，在含2.5%戊二醛的0.1 mol/L PB (pH7.2)中固定12~24 h，0.1 mol/L PB清洗2 h (中间换2~3次新液)；再用1%的锇酸固定1.5 h，用双蒸水洗至无锇酸气味；梯度酒精脱水，醋酸异戊酯置换，临界点干燥；IB-5离子溅射仪中镀铂；日立S-570扫描电子显微镜观察并拍照。</p></sec><sec id="s6_2_2"><title>2.2.2. 免疫表型检测</title><p>取第5代对数生长期的UC-MSC，0.25%胰蛋白酶-EDTA液消化，待大部分细胞脱离瓶底后，用无血清培养基中止消化，1000转/min &#215; 5 min收集细胞，再用含0.1% BSA的PBS悬浮，调整细胞密度为1 &#215; 10<sup>6</sup>个/ml，分别降入标记的鼠抗人CD90、鼠抗人CD105、鼠抗人CD73、鼠抗人CD44、鼠抗人CD45、鼠抗人CD34、鼠抗人HLA-DR 10 μl，另取一管做IgG同型对照，4℃避光孵育30min；PBS清洗两次，离心收集细胞，加入0.5ml PBS重悬，流式细胞仪上机检测。</p></sec><sec id="s6_2_3"><title>2.2.3. 诱导分化实验</title><p>1) 成骨细胞：取第5代对数生长的UC-MSC，约60%融合时加入成骨诱导培养基(含10%小牛血清，地塞米松0.1 umol/L，Vc 0.2 mmol/L，β-甘油磷酸钠50 mmol/L)，每3天全量换液一次，2周后行碱性磷酸酶染色和茜素红S染色。</p><p>2) 软骨细胞：取培养第5代处于对数生长期的UC-MSC，约60%融合时加入软骨诱导培养基(含10%小牛血清，TGF-β1 3 ng/mL，地塞米松0.1 umol/L，β-甘油磷酸钠5 mmol/L，Vc 0.2 mmol/L，胰岛素2 ug/mL，丙酮酸钠30 ug/ml，牛血清白蛋白0.4 mg/ml，亚硒酸2 ug/ml，亚油酸2 ug/ml)，诱导2周后甲苯胺蓝染色检测胶原表达，RT-PCR检测软骨特异性II型、X型胶原和aggrecan基因表达。</p></sec><sec id="s6_2_4"><title>2.2.4. 系统性红斑狼疮小鼠模型建立</title><p>取6~8周龄雌性BALB/c小鼠单次腹腔注射pristane 0.5mL，对照组单次腹腔注射PBS 0.5 mL，注射前及注射后每2周行流式细胞术(FCM)检测外周血中IFN-α分泌细胞(CD11b + Ly6Chigh)的比例及细胞活化状态B220 + Aβ1dhigh)，ELISA检测血清中自身抗体(anti-dsDNA，anti-sm RNP，antiribosomal P0)的含量。至6个月处死动物，FCM检测腹腔细胞中IFN-α分泌细胞(CD11b + Ly6Chigh)的比例和脾脏中细胞的活化(B220，Aβ1d)，采用直接免疫荧光法标记小鼠肾脏免疫球蛋白复合物及HE染色评估小鼠肾脏免疫复合物的沉积及损伤情况。饲养条件：室温25℃左右，湿度60%，每日12 h光照周期(6 am~6 pm)，分笼喂养，每笼5~6只，自由进食。</p></sec></sec><sec id="s6_3"><title>2.3. UC-MSC移植治疗系统性红斑狼疮小鼠有效性评价</title><sec id="s6_3_1"><title>2.3.1. 分组与给药</title><p>SLE小鼠随机分为模型组和治疗组，每组15只。对照组为健康小鼠，15只。对照组和模型组给予等量的生理盐水；治疗组给予UC-MSC 4 &#215; 10<sup>5</sup> cells/ml，0.2 ml，给药方式均为尾静脉注射(iv)。</p></sec><sec id="s6_3_2"><title>2.3.2. 指标检测</title><p>每日观察小鼠的疾病活动度评分、尿蛋白抗双链、肾脏病理情况、DNA (ds-DNA)抗体检测浓度等。</p><p>1) 尿蛋白浓度的检测</p><p>每三四周测定动物体质量及尿蛋白定量(24 h)。采用代谢笼留取小鼠24 h尿量。尿蛋白浓度测定采用Bradford法以小牛血清蛋白作为标准品，于分光光度计595 nm下测吸光度(A)值，绘制蛋白定量标准曲线，计算实验组和对照组小鼠24 h尿蛋白浓度值。</p><p>2) 小鼠肾脏病理学检查</p><p>每组取小鼠的肾脏组织于体积分数10%中性甲醛液固定24 h，乙醇脱水，石蜡包埋，切片，厚4 μm，苏木精–伊红染色，显微镜下观察小鼠肾脏细胞数、肾小球硬化、新月体的性质和数目、肾小球毛细血管袢坏死及肾小球毛细血管袢内血栓形成等。</p><p>3) 抗ds-DNA抗体检测</p><p>按照试剂盒操作说明，在标准品孔中加入标准品50 μL；待测样本孔中。</p><p>先加入待测样本10 μL，再加样本稀释液40 μL；37℃恒温箱温育30 min；重复洗板4次；每孔加入酶标工作液50 μL；37℃恒温箱温育30 min；重复洗板4次；每孔依次加入显色剂A、B液50 μL，平板混匀器混匀30 s，37℃避光显色15 min；取出酶标板，每孔加终止液50 μL，终止反应；用450 nm波长测量各孔的吸光度值(A值)；计算出标准曲线的直线回归方程。</p></sec></sec></sec><sec id="s7"><title>3. 实验结果</title><sec id="s7_1"><title>3.1. UC-MSC细胞培养及鉴定</title><sec id="s7_1_1"><title>3.1.1. UC-MSC细胞形态</title><p>倒置显微镜下观察，原代培养的MSCs细胞24 h后开始贴壁，7天后可见贴壁细胞呈纺锤状。第10~14天后去掉组织块，倒置显微镜下可见散在分布、大小不等、贴壁生长的细胞集落，细胞形态与骨髓来源MSCs相似，多为长梭形细胞，细胞折光性好，核仁明显。细胞融合度达到80%时进行传代，按照5 &#205; 10<sup>4</sup>细胞/ml的密度接种。接种后的MSCs 2 h后开始贴壁，接种第二天，细胞变为长梭形，生长迅速，接种第3~4天细胞即可达到80%~90%融合度(图1(A))。MSCs可传15代以上，细胞形态无明显变化。</p><p>扫描电子显微镜下可见大部分细胞表面光滑(图1(B))，少数梭形细胞有丰富的表面片状皱褶；透射电镜观察显示膜光滑有少量微绒毛的成纤维样细胞占大多数，该细胞核/质比约为1/5，细胞核常染色质丰富、分布均匀，图1(C)可见双核仁，核仁大而结构清晰，核膜完整，可见内质网、高尔基复合体、线粒体、溶酶体和一些髓鞘样小体，胞质中分别有大量核糖体和微丝。</p><p>图1. 体外培养的人UC-MSCs</p></sec><sec id="s7_1_2"><title>3.1.2. 细胞表型</title><p>第5代MSCs高表达CD90、CD73、CD105和CD44，低表达CD34、CD45和HLA-DR (见图2)；本实验结果表明，脐带来源的MSCs与骨髓、脐血等其他组织来源的MSCs流式检测表型一致。</p></sec><sec id="s7_1_3"><title>3.1.3. 细胞分化结果及其鉴定</title><p>加入成骨诱导培养基两三天后，细胞开始从长梭形缩短为多角形，细胞体积增大，诱导14天后茜素红S染色为阳性，碱性磷酸酶阳性细胞大幅增加，表现出成骨细胞的特点(图3(A)，图3(B))；加入软骨诱导培养基后，细胞由长梭形显著缩短为椭圆形，体积增大，甲苯胺蓝染色呈阳性(图4(A)~(C))，II型胶原免疫组化染色阳性(图4(D))。</p><p>图2. 流式细胞术检测UC-MSCs表型</p><p>图3. 体外诱导人UC-MSCs向成骨和脂肪细胞分化((A), (D)&#215;200; (B), (C)&#215;100)</p></sec></sec><sec id="s7_2"><title>3.2. 建立了完善的质量控制体系</title><p>参考国家政策文件、国际规范及行业规范确定细胞标准化检测体系的质控指标和检测流程。参考的文件主要有：《药品管理法》、《人体细胞治疗研究和制剂质量控制技术指导原则》、《干细胞制剂质量控制及临床前研究指导原则(试行)》、《细胞制品研究与评价技术指导原则(试行)》、《多潜能间充质干细胞最低标准》(国际细胞治疗协会，ISCT)、《基于人类细胞的治疗产品指南》(欧洲药品审评委员会)、《21CFR1271人用细胞组织和细胞的组织培养产品》(美国食品药品监督管理局)、《干细胞制剂制备质量管理自律规范》。</p><p>图4. 体外诱导人UC-MSCs向软骨细胞分化(&#215;100)</p><p>参考《中国药典》、国家标准、国际标准(如AAABB、FACT)等法规及行业规范进行具体检测指标质量标准的研究，包括原辅料质量标准的研究与确定、原代细胞质量标准的研究与确定、工作细胞质量标准的研究与确定、细胞终制品质量标准的研究与确定等。</p><p>检测方法的研究与确定主要分为6部分：</p><p>① 细胞生物学属性，研发并建立细胞形态、细胞染色体核型分析、代谢酶亚型谱分析、表面标志物检测、细胞存活率、生长活性、细胞纯度等快速准确的检测方法；</p><p>② 微生物学安全性，研发并建立无菌(细菌和真菌)、支原体、分支杆菌、细胞内外源致病因子、内毒素检测等高灵敏度、适应性强的检测方法；</p><p>③ 细胞生物学安全性，研发并建立细胞致瘤性、细胞促瘤性、细胞过敏反应、细胞毒性等检测方法；</p><p>④ 细胞生物学有效性，研究并建立细胞分化潜能、免疫调控能力评价、细胞特有的生物学性能评价等检测方法。</p><p>⑤ 一般检测，研发并建立细胞外观、细胞悬液浊度、可见异物等检测方法。</p><p>⑥ 残留检测，根据细胞的特殊工艺，分析细胞制品中可能含有的杂质情况，研究并建立杂质检测的方法。</p><p>主要内容有(图5)：</p><p>图5. 质量管理体系建立流程图</p></sec><sec id="s7_3"><title>3.3. 系统性红斑狼疮小鼠模型的建立</title><sec id="s7_3_1"><title>3.3.1. 小鼠血浆中自身抗体检测</title><p>Pristane处理组小鼠血浆中自身抗体含量明显高于PBS，对照组外周高滴度自身抗体的持续存在是SLE 最主要的病理特征之一，也是SLE小鼠模型是否和人类疾病病理模型相近的主要评价指标之一。为此，首先采用ELISA方法检测了pristane处理的不同时段收集的小鼠血浆中总IgG及抗dsDNA、ribosomal P0和sm RNP的IgG含量，该3种抗原属于SLE特异性的自身核抗原，其中抗ds-DNA IgG含量也是目前临床上SLE的主要特异性诊断指标。图6所示，pristane处理组血清中总IgG及anti-dsDNA、anti-ribosomal P0及anti-smRNP IgG含量从第2个月起开始持续上升，自第3个月起抗ribosomal P0 的自身抗体的水平已经明显高于PBS对照组，从第4个月起，抗ribosomal P0和抗sm-RNP的水平均显著高于PBS处理组，至6个月处死时3种抗自身抗体的IgG含量抗体达到最高，相对于对照组均明显升高(P &lt; 0.01)，表明pristane处理后可以导致小鼠逐渐产生抗自身核DNA和核蛋白的自身抗体，其中抗ribosomal P0及sm-RNP IgG的增高相对抗dsDNA IgG来说出现的时间更早，也更明显。</p></sec><sec id="s7_3_2"><title>3.3.2. 小鼠肾脏病理变化</title><p>6个月后处死小鼠，取新鲜肾脏制成石蜡切片，计数小鼠肾小球断面的细胞核数，计数了20个肾小球断面并取其平均值，显示pristane处理组小鼠肾小球断面平均细胞核数明显高于PBS对照组(图7)，表明处理组小鼠肾小球发生了明显的细胞性硬化症，处理组小鼠的这种肾脏损伤与大量IgG在肾脏的沉积相一致。</p><p>图6. 小鼠血清中总IgG及自身抗体含量</p><p>图7. 小鼠肾脏免疫复合物沉积及病理损伤</p></sec></sec><sec id="s7_4"><title>3.4. UC-MSC移植治疗系统性红斑狼疮小鼠有效性评估</title><sec id="s7_4_1"><title>3.4.1. UC-MSC移植对系统性红斑狼疮小鼠尿蛋白定量(24h)的影响</title><p>对照组小鼠从16周龄始，尿蛋白逐渐升高。治疗组小鼠在治疗的初期，尿蛋白也逐渐上升，但上升趋势较对照组明显减慢。32周时UC-MSC组水平低于模型组(P &lt; 0.01) (图8)。</p><p>图8. UC-MSCs移植对系统性红斑狼疮小鼠尿蛋白定量(24 h)的影响</p></sec><sec id="s7_4_2"><title>3.4.2. UC-MSC移植对系统性红斑狼疮小鼠肾脏病理学检查</title><p>模型组小鼠肾脏病理显示显著的病理改变(图9)，表现为肾小球硬化、肾小球系膜细胞增殖、基质增宽，并可见新月体形成，肾间质内大量淋巴细胞浸润。脐带MSCs组表现为系膜细胞，系膜基质轻至中度增生，局灶性硬化，偶尔可见的肾间质的炎症细胞的浸润。</p><p>图9. UC-MSC移植对系统性红斑狼疮小鼠肾脏病理的影响</p></sec><sec id="s7_4_3"><title>3.4.3. UC-MSC移植对狼疮鼠抗ds-DNA抗体的影响</title><p>UC-MSCs组(2.6 &#177; 0.9)抗ds-DNA抗体水平明显降低，与模型组(4.8 &#177; 0.7)相比差异有显著性意义，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Changes of serum antibodies after umbilical cord MSCs transplantation ( x &#175; &#177; s , A </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >ds-DNA</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >0.2 &#177; 0.4</td></tr><tr><td align="center" valign="middle" >模型组</td><td align="center" valign="middle" >4.8 &#177; 0.7</td></tr><tr><td align="center" valign="middle" >UC-MSC治疗组</td><td align="center" valign="middle" >2.6 &#177; 0.9<sup>a</sup></td></tr></tbody></table></table-wrap><p>表1. 脐带MSCs移植后血清抗体的变化 ( x &#175; &#177; s , A )</p><p><sup>a</sup>P &lt; 0.05, vs.模型组。</p></sec></sec></sec><sec id="s8"><title>4. 讨论</title><p>人脐带MSCs是一类具有自我更新、增殖和多向分化潜能的干细胞，具有来源丰富、易于采集、保存和运输、移植前无需清髓处理、避免伦理争议等诸多优点 [<xref ref-type="bibr" rid="hanspub.37775-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.37775-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.37775-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.37775-ref11">11</xref>]。由于MSCs没有MHC限制性，在异体MSCs移植时无排斥反应发生，而且MSCs在分化成其他细胞类型时仍保留其特性，临床上已将MSCs应用于组织工程、大剂量化疗后造血支持、治疗移植物抗宿主病等。</p><p>大量研究表明可通过多种途径调节炎症因子的释放，在体内外均可发挥免疫抑制作用 [<xref ref-type="bibr" rid="hanspub.37775-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.37775-ref13">13</xref>]，此外，MSCs还可诱导免疫耐受、抑制自身免疫反应，从而发挥治疗作用。目前认为MSCs的作用机制可能主要通过与免疫细胞(如T淋巴细胞，树突状细胞，B淋巴细胞等)直接接触发挥效应，还可能通过改变细胞因子分泌网络间接影响免疫细胞，但确切机制仍不清楚。</p><p>近年来对肾损伤疾病的研究也显示MSCs输注可促进肾损伤的结构修复和功能恢复，MSCs可迁移至受损的肾脏并分化为肾小管上皮细胞，加快肾小管细胞增殖速度 [<xref ref-type="bibr" rid="hanspub.37775-ref14">14</xref>]。大量研究结果表明健康人骨髓MSCs移植治疗狼疮鼠能显著降低尿蛋白和血抗ds-DNA抗体水平，狼疮鼠肾病理显著改善 [<xref ref-type="bibr" rid="hanspub.37775-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.37775-ref16">16</xref>]。结果发现，MSCs移植后，24 h尿蛋白定量降低、抗dsDNA抗体水平下降、肾脏病理改变明显好转，表明MSCs移植对狼疮肾炎具有治疗作用，这与国内外的研究报道相一致。实验结果提示MSCs移植可以通过抑制促炎因子的作用而发挥免疫抑制作用；同时，尿蛋白定量(24 h)降低、抗ds-DNA抗体水平下降，肾小球硬化、间质纤维化程度及间质炎症细胞浸润程度较对照组减轻，这些结果均表明MSCs对狼疮鼠肾脏病变具有修复作用。</p></sec><sec id="s9"><title>文章引用</title><p>宋珂慧,郭 伟. 用于治疗系统性红斑狼疮的脐带间充质干细胞的产品质量控制的研究Quality Control of Umbilical Cord Mesenchymal Stem Cells for the Treatment of Systemic Lupus Erythematosus[J]. 生物医学, 2020, 10(04): 82-94. https://doi.org/10.12677/HJBM.2020.104012</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.37775-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">阮光萍, 姚翔, 刘菊芬, 等. 人脐带间充质干细胞移植治疗系统性红斑狼疮[J]. 中国组织工程研究, 2015, 19(14): 2172-2178.</mixed-citation></ref><ref id="hanspub.37775-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Figueroa, F.E., Carrion, F., Villanueva, S. and Khoury, M. (2012) Mesenchymal Stem Cell Treatment for Autoimmune Diseases: A Critical Review. Biological Research, 45, 269-277. 
&lt;br&gt;https://doi.org/10.4067/S0716-97602012000300008</mixed-citation></ref><ref id="hanspub.37775-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">尹学红, 白力, 耿立霞. 间充质干细胞对免疫细胞的调节及其在自身免疫性疾病中的应用[J]. 细胞与分子免疫学杂志, 2016, 32(10): 1435-1438.</mixed-citation></ref><ref id="hanspub.37775-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Li, X., Liu, L., Meng, D.F., Wang, D.D., Zhang, J.Y. and Shi, D.Y. (2012) Enhanced Apoptosis and Senescence of Bone-Marrow-Derived Mesenchymal Stem Cells in Patients with Systemic Lupus Erythematosus. Stem Cells and Development, 21, 2387-2394. &lt;br&gt;https://doi.org/10.1089/scd.2011.0447</mixed-citation></ref><ref id="hanspub.37775-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Chen, H.F., Shi, B.Y., Feng, X.B., et al. (2015) Leptin and Neutrophil-Activating Peptide 2 Promote Mesenchymal Stem Cell Senescence through Activation of the Phosphatidylinositol 3-Kinase/Akt Pathway in Patients with Systemic Lupus Erythematosus. Systemic Lupus Erythematosus, 67, 2383-2393. &lt;br&gt;https://doi.org/10.1002/art.39196</mixed-citation></ref><ref id="hanspub.37775-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Gu, Z.F., Tan, W., Feng, G.J., Meng, Y., Shen, B.Y., Liu, H. and Cheng, C. (2014) Wnt/β Catenin Signaling Mediates the Senescence of Bone Marrow-Mesenchymal Stem Cells from Systemic Lupus Erythematosus Patients through the p53/p21 Pathway. Molecular and Cellular Biochemistry, 387, 27-37. &lt;br&gt;https://doi.org/10.1007/s11010-013-1866-5</mixed-citation></ref><ref id="hanspub.37775-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tang, Y., Ma, X.L., Zhang, H.Y., et al. (2012) Gene Expression Profile Reveals Abnormalities of Multiple Signaling Pathways Inmesenchymal Stem Cell Derived from Patients with Systemic Lupus Erythematosus. Clinical and Developmental Immunology, 2012, Article ID: 826182. &lt;br&gt;https://doi.org/10.1155/2012/826182</mixed-citation></ref><ref id="hanspub.37775-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Prockop, D.J. (1997) Marrow Stromal Cells as Stem Cells for Nonhematopoietic Tissues. Science, 276, 71-74.  
&lt;br&gt;https://doi.org/10.1126/science.276.5309.71</mixed-citation></ref><ref id="hanspub.37775-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Sanchez-Ramos, J., Song, S., Cardozo-Peleza, F., et al. (2000) Adult Bone Marrow Stromal Cells Differentiate into Neural Cells in Vitro. Experimental Neurology, 164, 247-256. &lt;br&gt;https://doi.org/10.1006/exnr.2000.7389</mixed-citation></ref><ref id="hanspub.37775-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Saulnier, N., Lattanzi, W., Puglisi, M.A., et al. (2009) Mesenchymal Stromal Cells Multipotency and Plasticity: Induction toward the Hepatic Lineage. European Review for Medical and Pharmacological Sciences, 13, 71-78.</mixed-citation></ref><ref id="hanspub.37775-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chun, H.Y., Chung, J.W., Kim, H.A., et al. (2007) Cytokine IL-6 and IL-10 as Biomarkers in Systemic Lupus Erythematosus. Journal of Clinical Immunology, 27, 461-466. &lt;br&gt;https://doi.org/10.1007/s10875-007-9104-0</mixed-citation></ref><ref id="hanspub.37775-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Aggarwal, S. and Pittenger, M.F. (2005) Human Mesenchymal Stem Cells Modulate Allogeneic Immune Cell Responses. Blood, 105, 1815-1822. &lt;br&gt;https://doi.org/10.1182/blood-2004-04-1559</mixed-citation></ref><ref id="hanspub.37775-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sotiropoulou, P.A., Perez, S.A., Gritzapis, A.D., Baxevanis, C.N. and Papamichail, M. (2006) Interactions between Human Mesenchymal Stem Cells and Natural Killer Cells. STEM CELLS, 24, 74-85. 
&lt;br&gt;https://doi.org/10.1634/stemcells.2004-0359</mixed-citation></ref><ref id="hanspub.37775-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Aggarwal, S. and Gumey, A.L. (2002) IL-17: Prototype Member of an Emerging Cytokine Family. Journal of Leukocyte Biology, 71, 1-8.</mixed-citation></ref><ref id="hanspub.37775-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, K.X., Zhang, H.Y., Sun, L.Y., et al. (2009) Human Bone Marrow Megenehymal Stem Cell Transplantation Amelioretes the Autoimmune Progression in MRL/lpr Mice. Cellular &amp; Molecular Immunology, 5, 417-424.</mixed-citation></ref><ref id="hanspub.37775-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Leandro, M.J., Cambridge, G., Edwards, J.C., Ehrenstein, M.R. and Isenberg, D.A. (2005) B-Cell Depletion in the Treatment of Patients with Systemic Lupus Erythematosus: A Longitudinal Analysis of 24 Patients. Rheumatology, 44, 1542-1545. &lt;br&gt;https://doi.org/10.1093/rheumatology/kei080</mixed-citation></ref></ref-list></back></article>